RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+12.85%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$2.44B
AUM Growth
+$2.44B
(-5.2%)
Cap. Flow
-$46.4M
Cap. Flow
% of AUM
-1.9%
Top 10 Holdings %
Top 10 Hldgs %
50.14%
Holding
73
New
3
Increased
9
Reduced
33
Closed
4
Top Buys
| 1 |
Akero Therapeutics
AKRO
|
$57.1M |
| 2 |
Prime Medicine
PRME
|
$41M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$37.8M |
| 4 |
Replimune Group
REPL
|
$32.3M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$23.6M |
Top Sells
| 1 |
argenx
ARGX
|
$49.8M |
| 2 |
Prothena Corp
PRTA
|
$31.9M |
| 3 |
ONEM
1Life Healthcare, Inc. Common Stock
ONEM
|
$29.4M |
| 4 |
The Beauty Health Co
SKIN
|
$24.9M |
| 5 |
LivaNova
LIVN
|
$23.9M |
Sector Composition
| 1 | Healthcare | 98.91% |
| 2 | Industrials | 0.92% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ventyx Biosciences
VTYX
$184M
| $29.3M | 1.2% |
894,974
-470,026
| -34% | -$15.4M |
|
27
ADC Therapeutics
ADCT
$370M
| $29.1M | 1.19% |
7,590,849
+78,820
| +1% | +$303K |
|
28
Stryker
SYK
$149B
| $25.9M | 1.06% |
105,880
-51,441
| -33% | -$12.6M |
|
29
Entrada Therapeutics
TRDA
$202M
| $25.1M | 1.03% |
1,854,108
-100,311
| -5% | -$1.36M |
|
|
GRTS
30
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $23.9M | 0.98% |
6,931,460
-21,300
| -0.3% | -$73.5K |
|
|
VERV
31
DELISTED
Verve Therapeutics
VERV
| $23.6M | 0.97% |
1,221,903
-283,223
| -19% | -$5.48M |
|
32
Centene
CNC
$14.8B
| $23.1M | 0.94% |
281,260
-1,200
| -0.4% | -$98.4K |
|
|
AUGX
33
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $22.4M | 0.92% |
14,380,327
| – | – |
|
|
ALLK
34
DELISTED
Allakos
ALLK
| $21.4M | 0.88% |
2,545,275
| – | – |
|
35
Atara Biotherapeutics
ATRA
$88.7M
| $20.5M | 0.84% |
6,242,756
| – | – |
|
36
Elevance Health
ELV
$72.4B
| $20M | 0.82% |
38,970
-31,517
| -45% | -$16.2M |
|
37
Immunovant
IMVT
$2.91B
| $19.3M | 0.79% |
+1,088,131
| New | +$19.3M |
|
38
Scholar Rock
SRRK
$3.3B
| $19M | 0.78% |
2,095,820
-1,044,206
| -33% | -$9.45M |
|
39
Annexon
ANNX
$225M
| $18.1M | 0.74% |
3,503,190
| – | – |
|
40
Stevanato
STVN
$6.36B
| $16.9M | 0.69% |
942,525
-4,300
| -0.5% | -$77.3K |
|
41
Absci
ABSI
$356M
| $16.9M | 0.69% |
8,031,094
| – | – |
|
42
RAPT Therapeutics
RAPT
$187M
| $15.5M | 0.64% |
784,832
| – | – |
|
43
Revolution Medicines
RVMD
$7.43B
| $14.9M | 0.61% |
625,000
| – | – |
|
44
Shattuck Labs
STTK
$61.3M
| $12.9M | 0.53% |
5,619,914
| – | – |
|
|
MDVL
45
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
| $10.4M | 0.42% |
34,604,516
| – | – |
|
46
Ionis Pharmaceuticals
IONS
$9.64B
| $10.1M | 0.41% |
266,187
-141,472
| -35% | -$5.34M |
|
47
LAVA Therapeutics
LVTX
$41.3M
| $9.86M | 0.4% |
2,816,196
| – | – |
|
|
KLRS
48
Kalaris Therapeutics, Inc. Common Stock
KLRS
$85.5M
| $9.79M | 0.4% |
1,907,969
| – | – |
|
|
SNCE
49
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $8.22M | 0.34% |
19,808,234
| – | – |
|
50
ALX Oncology
ALXO
$54.6M
| $6.85M | 0.28% |
607,470
-144,627
| -19% | -$1.63M |
|